Nivolumab

DALLAS — Neoadjuvant immunotherapy did not increase risk for complications among patients who underwent surgery for head and neck cancers, according to study results presented at American Head & Neck Society Annual Meeting.

Esophageal cancer is one of the deadliest forms of cancer with an estimated 19,260 diagnoses and 15,530 deaths in the United States last year, the American Association for Cancer Research reported.

Neoadjuvant nivolumab plus chemotherapy significantly improved EFS in stage IB to stage IIIA resectable non-small cell lung cancer, according to research presented at American Association for Cancer Research Annual Meeting.

Mark W. Ball, MD, spoke with Healio about an ongoing phase 2 study assessing the use of cytoreductive stereotactic hypofractionated radiotherapy along with ipilimumab and nivolumab in patients with metastatic renal cell carcinoma.

The FDA approved relatlimab plus nivolumab for treatment of patients aged 12 years or older with unresectable or metastatic melanoma.

Relatlimab plus nivolumab continued to demonstrate a PFS benefit compared with nivolumab alone for patients with previously untreated metastatic or unresectable melanoma, according to a study presented during an ASCO Plenary Series session.

Nivolumab alone or in combination with ipilimumab was safe and well-tolerated in patients with resectable hepatocellular carcinoma in the perioperative setting, according to a study published in Lancet Gastroenterology and Hepatology.

A phase 3 trial designed to assess the addition of bempegaldesleukin to nivolumab for previously untreated unresectable or metastatic melanoma failed to meet its primary endpoint, according to the agents’ manufacturers.

The FDA approved nivolumab with platinum doublet chemotherapy as neoadjuvant treatment for adults with resectable non-small cell lung cancer.

The FDA granted priority review to nivolumab for use with chemotherapy as neoadjuvant treatment of patients with resectable non-small cell lung cancer.